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Abstract
Background: When designing and analysing clinical trials, using previous relevant information, perhaps in the form
of evidence syntheses, can reduce research waste. We conducted the INVEST (INVestigating the use of Evidence
Synthesis in the design and analysis of clinical Trials) survey to summarise the current use of evidence synthesis in
trial design and analysis, to capture opinions of trialists and methodologists on such use, and to understand any barriers.
Methods: Our sampling frame was all delegates attending the International Clinical Trials Methodology Conference in
November 2015. Respondents were asked to indicate (1) their views on the use of evidence synthesis in trial design and
analysis, (2) their own use during the past 10 years and (3) the three greatest barriers to use in practice.
Results: Of approximately 638 attendees of the conference, 106 (17%) completed the survey, half of whom were
statisticians. Support was generally high for using a description of previous evidence, a systematic review or a
meta-analysis in trial design. Generally, respondents did not seem to be using evidence syntheses as often as
they felt they should. For example, only 50% (42/84 relevant respondents) had used a meta-analysis to inform
whether a trial is needed compared with 74% (62/84) indicating that this is desirable. Only 6% (5/81 relevant
respondents) had used a value of information analysis to inform sample size calculations versus 22% (18/81)
indicating support for this. Surprisingly large numbers of participants indicated support for, and previous use of,
evidence syntheses in trial analysis. For example, 79% (79/100) of respondents indicated that external information
about the treatment effect should be used to inform aspects of the analysis. The greatest perceived barrier to
using evidence synthesis methods in trial design or analysis was time constraints, followed by a belief that the
new trial was the first in the area.
Conclusions: Evidence syntheses can be resource-intensive, but their use in informing the design, conduct and
analysis of clinical trials is widely considered desirable. We advocate additional research, training and investment
in resources dedicated to ways in which evidence syntheses can be undertaken more efficiently, offering the
potential for cost savings in the long term.
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Background
When designing and analysing a clinical trial, it is im-
portant to look at previous evidence and use relevant
information to inform aspects of the new trial, thereby
reducing waste in research [1]. Previous evidence should
firstly be used to assess whether a gap in the current evi-
dence base justifies a new trial [2, 3]. Subsequently there
are many possible uses of previous evidence in informing
the planning of a trial before it begins, monitoring of a trial
in progress, and analysis and reporting of the results of a
new trial alongside other relevant research [4, 5] (Table 1).
In the design stage, existing evidence can be used to refine
the choice of population, control treatment, intervention,
definition of an outcome and duration of follow-up in order
to maximise relevance of the findings [6, 7]. Previous
studies might inform the choice of most appropriate
statistical analysis (e.g. based on how rare the outcome
is), while quantitative information on the likely treatment
effect or the event rate in the control group might be used
in sample size calculations [8, 9]. In the analysis stage,
external information could be used to improve precision
in estimation as part of a secondary analysis, particularly
for parameters that are poorly estimated; for example, the
intra-class correlation coefficient (ICC) in a cluster rando-
mised trial [10, 11] or baseline event rates if events are
rare. To aid interpretation of trial results in the context of
relevant research [12], we might be interested in examin-
ing results from an updated meta-analysis [13, 14] or the
results of a Bayesian analysis of the new trial in which an
informative prior distribution for the intervention effect
(based on results of earlier studies) has been incorporated.
The analyst could also attempt to account for potential
flaws in the methodology of the new trial, such as the
allocated treatment being unblinded to the patient or
personnel, which can cause bias in the treatment effect
estimate [15]. External evidence about such bias might
come from ‘meta-epidemiological’ studies and could be
used to adjust the treatment effect estimate from the
new study [16], allowing the analyst to assess the sensi-
tivity of the findings.
In a survey of 24 investigators whose trials were in-
cluded in an update of a Cochrane review, only 8
(33%) indicated that a previous review had influenced
trial design and only 2 (8%) had used the previous
Cochrane review [2, 3]. More recently, reviews of trials
funded by the National Institute for Health Research
(NIHR) Health Technology Assessment (HTA) programme
found that the majority (77% of those funded between 2006
and 2008 [4] and 100% of those funded in 2013 [7]) refer-
enced a systematic review in the funding application. When
a systematic review was not referenced, there were valid
reasons for this such as there being no relevant systematic
review addressing the proposed research question [7].
Arguably of more interest is whether and how a cited
review was used to inform trial design. The recent review
of Bhurke et al. [7] found that 94% (32/34) of the trials ex-
amined used the referenced systematic review to justify
the treatment comparison in the new trial, but that other
uses were relatively infrequent. The other most common
uses were in selection of a definition or outcome (16%), to
inform the standard deviation (9%) or to inform duration
of follow-up (6%). Tierney et al. describe examples of how
meta-analyses of individual participant data (IPD) have
informed trial design, conduct and analysis in practice
[17]. To our knowledge, there are no recent studies inves-
tigating the extent of the use of evidence synthesis in the
design of trials funded through streams other than the
NIHR HTA programme or in trial analyses.
Here, we report results from the INVEST (INVestigating
the use of Evidence Synthesis in the design of clinical
Trials) survey. The main objectives of the survey were
to summarise the current use of evidence synthesis in
trial design and analysis across clinical trials teams, to
capture current opinions of trialists and methodologists
on such use, and to understand any barriers to use in
practice.
Methods
The sampling frame consisted of all delegates at the
2-day International Clinical Trials Methodology Confer-
ence (ICTMC) on 16–17 November 2015. The conference
was open to both those involved and those who have an
interest in clinical trials methodology. Approximately 638
people registered to attend the conference across a range
of disciplines including trialists, clinicians, statisticians,
health economists, information specialists and qualitative
researchers. Ninety-five percent of the registered delegates
were from the UK and the Republic of Ireland, with the
remaining 5% from Australia, Canada, Denmark, France,
Germany, Holland and the United States. The main UK
research centres represented were Aberdeen, Birmingham,
Bristol, Cambridge, Cardiff, Coventry, Glasgow, Leeds,
London, Liverpool, Manchester, Oxford and Southampton.
Conference delegates were first invited to take part in the
survey during the opening plenary session, then by re-
searchers from the INVEST team during breaks. The
survey could be completed either on paper or online,
with a closing date of 18 December 2015. The survey in
full is available in Additional file 1.
Following details about their job role, job setting and the
length of time that they had spent working in clinical trials,
respondents who indicated that they had been involved in
trial design (and/or analysis) were further asked questions
about whether, and how, they have used evidence synthesis
in practice. All respondents were then asked about their
views on the use of evidence synthesis in trial design and
analysis. They were also asked to rank what they considered
to be the three greatest barriers to such use. There were
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nine potential barriers listed including an ‘other’ category
allowing free text. The subsets of respondents who indicated
that they had been involved in trial design (and/or analysis)
were used to contrast views on whether evidence synthesis
methods should be used versus current use in practice.
The use of evidence synthesis to inform trial design
Respondents who indicated they had personally been in-
volved in trial design were asked to consider any trials in
which they had been involved over the last 10 years and
to specify, if applicable, how evidence synthesis had been
used in practice. A matrix style layout was chosen to
allow multiple responses, with rows for each area of trial
design and columns for types of evidence synthesis. In
addition to (1) a description of previous evidence, (2) a
systematic review and (3) a meta-analysis, we listed three
evidence synthesis methods that extend meta-analysis:
(4) network meta-analysis (NMA) which allows the
Table 1 Summary of opportunities for evidence synthesis to inform design, conduct and analysis of a clinical trial
Stages of a clinical trial Opportunities in which previous evidence might be used
Prior to design To justify the need for a new trial in light of the existing evidence base.
A systematic literature review and, where appropriate, quantitative synthesis, could be used to assess the need for
the new trial [31, 32]. If there are no relevant previous trials, a search strategy might be requested by funders, such
as the National Institute for Health Research (NIHR), to support this. Relevant systematic reviews might include existing
clinical trials, early-phase trials, nonrandomised comparisons, animal studies or qualitative research studies [7].
Design Choice of population.
A systematic review may highlight the population and particular subgroups that warrant further investigation [17].
Choice of interventions and comparators.
Results from evidence syntheses, including network meta-analyses, decision models and value of information analyses,
can be used to choose which interventions and comparators to trial [33] and characteristics of these, e.g. dose or
duration of treatment [4, 17].
Choice of outcomes and length of follow-up.
A systematic review may help inform the choice of outcomes [4, 7] in a new trial and how they should be defined
and, if relevant, the duration of follow-up [17]. For example, a systematic review may highlight adverse events that
should be monitored, in particular events that are expected and related.
Sample size calculations
A systematic review and/or meta-analysis may provide information on the parameters needed for sample size
calculations [4, 17] such as the standard deviation, control group outcome rates, plausible effect sizes, loss to follow-up
and correlation coefficients [7]. Alternatively, expected value of sample information calculations can be used to assess
the ability of a new trial to inform cost-effectiveness assessment of the intervention and reduce decision uncertainty [29].
Recruitment and consent.
For example, good or poor recruitment rates in previous relevant trials can inform site selection in a new multicentre
trial [4].
Monitoring (conduct) To deal with adverse events
Observed adverse event rates can be compared with predictions from a synthesis of historic data to see if they are
higher than expected by chance [34].
To decide whether to stop an ongoing trial
Emerging trial results considered in the context of results from previous studies might be used to make the decision to
stop a trial early [17].
Analysis To inform the statistical analysis plan
Factors, such as measures of effects (event rates, mean difference, etc.) from previous trials, might influence the choice
of statistical model. Prognostic or predictive factors identified though evidence synthesis may be used to stratify or
adjust trial analyses [17]. Choice of the most important covariates to be recorded for imputation modelling might be
informed by patterns of missing data in previous trials.
To assess the trial treatment effect in the context of existing evidence
An existing meta-analysis might be used to form a prior distribution for the treatment effect in a new study which can
then be updated using the trial data in a Bayesian statistical analysis.
To adjust for potential biases.
External evidence about typical biases associated with undesirable study characteristics, e.g. inadequate blinding, might
come from ‘meta-epidemiological’ studies [35], allowing the analyst to assess the sensitivity of the findings to alternative
model assumptions.
To inform secondary parameters.
External evidence might be used to improve the estimation of ‘nuisance’ parameters involved in trial analysis which are
often poorly estimated, such as the intra-class correlation coefficient (ICC) in cluster randomised trials [10] and between-
centre variability in multicentre trials.
Reporting To report the new trial results in the context of the wider evidence base.
An updated systematic review [12] or meta-analysis including the new trial results [36] should be reported to put the
results in the context of the wider evidence base [17].
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simultaneous comparison of the effectiveness of multiple
interventions through the use of direct and indirect evi-
dence, (5) an economic decision model which can be used
to evaluate intervention effects formally in the context of
other factors, such as costs and potential harms, and make
decisions on the use of interventions in practice, (6) a
value of information (VoI) analysis which is sometimes
used to assess whether there is value in conducting a new
study, and to identify the optimal design for such a study
within an analytical modelling framework [18]. A final
option of ‘none of these methods’ was included. Re-
spondents were provided with a brief definition of these
evidence synthesis methods to reduce ambiguity. The
areas of trial design listed were: (1) whether a trial is
needed, (2) the choice of population, (3) the choice of
interventions, (4) the choice of outcomes and follow-up
time and (5) sample size calculations. Respondents were
also asked to indicate whether any evidence synthesis used
had been performed by the trial team or previously
published by others.
We also asked all respondents which of the listed evi-
dence synthesis methods they thought should be used to
inform aspects of trial design. This question was formatted
to match the earlier question about how those involved in
trial design were using evidence synthesis methods, facili-
tating comparison between ideal and current practices.
The use of evidence synthesis to inform trial analysis
Respondents who indicated they had personally been
involved in trial analysis were asked which (if any) of
three types of external evidence they had used in practice,
during the last 10 years: (1) external information about
the treatment effect (including a meta-analysis), (2) evi-
dence around the likely size of potential biases arising
from trial conduct (e.g. blinding infeasible) and (3) other
quantities involved in the analysis (e.g. correlations or
baseline event rates).
We asked all survey respondents whether each of
these three types of external evidence should be used to
inform trial analysis. For each of these, the options were
‘yes’, ‘no’ and ‘don’t know’. An overall ‘don’t understand’
response was also included since we anticipated that
some of these uses of evidence synthesis might be new
concepts to some respondents.
Analysis of survey responses
Our analysis is descriptive, as sample sizes were not suffi-
cient for a robust assessment of associations or subgroup
comparisons. Missing responses were excluded from
denominators and are indicated in footnotes in the
tables that follow.
For the subsets of respondents involved in trial design
or analysis, we compared their responses for desirability
versus actual use of evidence synthesis. For each of the
five aspects of trial design, we categorised each respondent
who indicated they had been involved in trial design into
one of the following: ‘used and think desirable’, ‘used but
don’t think desirable’, ‘not used and don’t think desirable’
and ‘not used but think desirable’. For each of the three
aspects of trial analysis, we added three categories to these
options: ‘used and don’t know whether desirable’, ‘not used
and don’t know whether desirable’ and ‘don’t understand’.
To summarise responses about the three greatest barriers
to the use of evidence synthesis, we assigned three points
to the first (greatest perceived) barrier, two to the second
and one to the third for each respondent. If a respondent
had ticked three barriers but not indicated a ranking, each
was assigned two points. No points were allocated for
respondents who did not answer the question. For each
potential barrier, the scores were then summated across
respondents, so that higher overall scores indicated greater
perceived barriers.
Although highly exploratory in nature because of small
numbers, we examined answers to specific questions for
two subgroups: the perceived barriers to the use of evi-
dence synthesis in practice by statisticians specifically,
statisticians’ use versus perceived desirability of using
evidence synthesis in trial analysis, and the views of
health economists on VoI analyses.
Results
There were 106 respondents, of whom 54 (51%) were stat-
isticians, 8 (8%) were health economists and 18 (17%)
worked in trial management. These are overlapping cat-
egories, i.e. respondents were asked to select all roles that
applied to them. All respondents had spent some time
working in the area of trials: 86 (81%) for at least 3 years
and 32 (30%) for more than 10 years. Ninety-six (91%)
respondents indicated that they had been involved in the
design, setting up or running of trials (77 (80%) in a clin-
ical trials unit and 9 (9%) in industry). Eighty-five (80%)
indicated that they had been involved in trial design, 71
(67%) in trial conduct, 73 (69%) in statistical analysis and
52 (49%) had been involved in undertaking a systematic
review of trials. Only three (3%) respondents indicated
that they had not been involved in any of these. Full
details are shown in Additional file 2: Table S1.
The use of evidence synthesis to inform trial design
Figure 1 summarises the views of respondents on the
desirability of using evidence synthesis in trial design.
Support for using a description of previous evidence or a
systematic review to inform each aspect listed was high.
For most aspects of design, support was slightly higher
for a simple description of previous evidence than a
systematic review. In contrast, there was slightly more
support for a systematic review to inform whether a trial
is needed (92/104 or 89% systematic review versus 75/104
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or 72% description of previous evidence) and the choice of
interventions (78/103, 76% versus 74/103, 72%, re-
spectively). Over 50% of respondents also felt that a
meta-analysis should be used to inform whether a trial
is needed, the choice of interventions and the sample
size. Fewer respondents indicated support for the use
of more complex analyses (NMA, decision models and
VoI analyses). For example, only 19% (20/101 respon-
dents) indicated that VoI analyses should be used to
inform sample size calculations. Of these respondents,
55% (11/20 respondents) were statisticians and 20%
(4/20 respondents) were health economists including
one person who identified themselves in both roles.
However, six of the eight health economists (75%) sup-
ported such use of VoI calculations across at least one
aspect of design. All respondents indicated support for
using some form of evidence synthesis in at least three
of the five aspects of trial design that were listed.
Seven respondents, all of whom had experience in trial
design, suggested that no form of evidence synthesis
was required for one or two specific aspects, most
commonly ‘choice of outcomes and follow-up time’ (3/
101 or 3% of respondents). Full results are shown in
Additional file 3: Table S2.
Of the 85 respondents who indicated involvement in
trial design, Fig. 2 contrasts their views on how evi-
dence synthesis methods should be used versus their
own use during the last 10 years. Full results are shown
in Additional file 3: Table S3. Slightly more respondents
indicated that they had used a description of previous
evidence to inform aspects of trial design than had indi-
cated that such use was desirable. For example, 82%
(69/84) had used a description of previous evidence to
decide whether a trial is needed, compared with 71%
(60/84) indicating support for such use. Of the 69 re-
spondents who had used a description of previous evi-
dence in this way, 14 (20%) did not indicate that such
use was desirable. In contrast, our results suggested
that trial design practitioners would like to be using
each of the other five types of evidence synthesis more
than they currently do in practice. This pattern was
consistent across all aspects of trial design. For example,
only 50% (42/84) of respondents had used a meta-analysis
to inform whether a trial is needed, whereas 74% (62/84)
thought that it was desirable. Ninety-three percent of
those who had used a meta-analysis to inform whether a
trial is needed (39/42) felt that such use was desirable.
Some 96% (78/81) of respondents claimed to have used
some form of evidence synthesis to inform sample size
calculations in the last 10 years, close to the 99% (80/81)
who indicated support for such use (data not shown).
Making the same comparison but excluding the less
formal ‘description of previous evidence’, we found a
larger discrepancy: 62% (50/81) had used evidence syn-
thesis methods to inform sample size calculations, com-
pared with 84% (68/81) indicating that this is desirable
Fig. 1 Views of respondents on whether evidence synthesis methods should be used to inform trial design. The type of evidence synthesis
method is summarised across five aspects of trial design: whether a trial is needed (n = 104), choice of population (n = 103), choice of
interventions (n = 103), choice of outcomes and follow-up time (n = 101), sample size (n = 103)
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(data not shown). Only 6% (5/81) of respondents had
used a VoI analysis to inform sample size calculations,
compared with 22% (18/81) indicating that VoI analysis
should be used for this. All five respondents who had
used VoI in this way were in support of its use. For all
types of evidence synthesis methods except VoI ana-
lyses, which was mostly conducted by the clinical trials
team, the use of previously published evidence synthe-
ses was most common (see Additional file 3: Table S4).
The use of evidence synthesis to inform trial analysis
Seventy-nine percent (79/100) of respondents indicated
that external information about the treatment effect should
be used to inform aspects of the analysis (see Fig. 3;
Additional file 4: Table S5). Similarly, 69% (69/100)
expressed support for using external information related
to potential biases in trial analysis and 67% (67/100) for
the use of external evidence on other quantities which are
usually poorly estimated. While only a few respondents
(5% or less) indicated that external evidence should not be
used in these ways, between 15 and 30% selected the
‘don’t know’ or ‘don’t understand’ options.
Seventy-three out of one hundred and six (69%) respon-
dents were involved in trial analysis. Figure 4 contrasts the
views of this subsample on how evidence synthesis methods
should be used to inform aspects of analysis versus their
own use in practice. 52% (35/68) indicated that, during the
past 10 years, they had used external information about the
treatment effect to inform trial analysis, compared with
79% (54/68) indicating support for such use. 97% of those
who had used external information in this way (34/35) felt
that such use was desirable. While 63% (20/32) of respon-
dents who had not used external information about the
treatment effect in trial analysis also felt such use was desir-
able, 22% (7/32) were not sure. Similar patterns were seen
for using external evidence on potential biases and other
quantities. Full results are shown in Additional file 4: Table
S6. A sensitivity analysis including only statisticians sug-
gested slightly less use of external evidence in each of the
three areas (see Additional file 4: Figure S1).
Barriers to the use of evidence synthesis methods
Figure 5 shows the barriers to using evidence synthesis,
ordered by their perceived importance. The bars show
the total number of points awarded to each barrier, split
by the number of points it acquired by being ranked the
first, second and third greatest barrier. 87% (90/103) of
respondents answered this question. By far the greatest
perceived barrier was time constraints. This was
followed by a belief that the trial was the first in the area
and a belief that previous trials were different from the
current trial. Of those selecting ‘other’, reasons included
complexity of the trials and the ‘chief investigator had
more evidence than previously published information.’
Fig. 2 Comparisons between desirable and current practice in the use of evidence synthesis methods in trial design. This is summarised by type
of evidence synthesis method, among survey respondents involved in trial design to inform five aspects of trial design: whether a trial is needed
(n = 84), choice of population (n = 82), choice of interventions (n = 82), choice of outcomes and follow-up time (n = 81), sample size (n = 81). Numbers
displayed are percentages
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‘Objections to using evidence syntheses (from you or
colleagues)’ was the lowest scoring barrier of those
listed. The conclusions remained unchanged when the
analysis was restricted to statisticians only (data not
shown).
Discussion
Our INVEST survey indicates a high level of support for
the use of evidence synthesis to inform aspects of trial
design and analysis. Support was generally high for using
a description of previous evidence, a systematic review
Fig. 4 Comparisons between desirable and current practice in the use of evidence synthesis methods in trial analysis. This is summarised among
survey respondents involved in trial analysis to inform three aspects of trial analysis: the treatment effect (n = 68), potential biases arising from trial
conduct (n = 69) and other quantities (n = 68). Numbers displayed as percentages
Fig. 3 Views of respondents on whether evidence synthesis should be used to inform trial analysis. This is summarised across three aspects of
trial analysis: the treatment effect, potential biases arising from trial conduct and other quantities (of n = 100 people who answered this question)
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or a meta-analysis when designing a trial. Fewer re-
spondents indicated support for the use of NMA, deci-
sion models and VoI analyses. Only a few respondents
(approximately 5%) felt that external evidence about
particular parameters should not be used in the analysis
of a trial; however, many (up to 20%) did not know if
such evidence should be used in practice. Our results
indicate some discrepancies between the evidence syn-
thesis methods that people think should be used and
what they are using in current practice. In particular,
respondents did not appear to be using systematic re-
views, meta-analyses, NMAs, decision models and VoI
analyses as much as they wanted across all aspects of
trial design. The greatest perceived barrier to using evi-
dence synthesis methods in trial design or analysis was
time constraints, followed by a belief that the new trial
was the first in the area.
The sampling frame was approximately 638 people,
but only 106 completed the survey, providing a response
rate of approximately 17% and a potential for selection
bias. We were unable to obtain information on the char-
acteristics of the nonrespondents which would have en-
abled us to explore the representativeness of our sample,
but it is possible that respondents were more enthusiastic
about evidence synthesis methods than nonrespondents.
Some 95% of our sampling frame were from the UK and
the Republic of Ireland, so the results may not be generalis-
able to the international clinical trials community. Further,
our sampling frame consisted of conference delegates closely
involved in trial design and analysis, who are likely to
have a strong interest in promoting good practice. As
such, we might expect our sample to answer some of
the questions more favourably than the wider popula-
tion of people involved in clinical trials. In particular,
half of respondents were statisticians (51%), who may
be expected to be more open to advanced statistical
methods (such as using evidence syntheses to improve
precision in estimates of some parameters) compared
with other contributors to the design, conduct or delivery
of trials. Statisticians are also influential members of the
multidisciplinary teams that are involved in trial design
and may be useful advocates for the increased use of avail-
able evidence in trial design. Although it would have been
interesting to explore differences across research centres
and countries, we chose not to collect such geographical
data to protect anonymity and minimise the burden of
survey completion. To summarise the barriers to the use
of evidence synthesis, we assigned scores based on an
arbitrary assumption of linearity, i.e. such that an indi-
vidual’s highest ranked barrier is three times as import-
ant as their third barrier. These scores, although
helpful for summarising data, might not reflect respon-
dents’ true views. We intended all listed barriers to be
interpreted as reasons why a trial team might not seek
or carry out evidence synthesis. However, it is possible
that some respondents who chose ‘Believed to be the
Fig. 5 Barriers to the use of evidence synthesis (higher scores indicate greatest perceived barriers). Three points were assigned to the greatest
barrier, 2 points to the second and 1 to the third. For example, 38 respondents ranked time constraints as the greatest barrier (3 × 38 = 114 points), 21
ranked it second (2 × 21 = 42) and 11 ranked it third (1 × 11 = 11)
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first trial in the area’ could have been thinking of the
situation where a literature search or systematic review
reveals no previous trials. The extent of this barrier
would then be overestimated.
In trial design, for both whether a trial was needed and
for choosing an intervention, more respondents said that
a systematic review, rather than a less formal description
of previous evidence, should be used. It therefore seems
that respondents felt the need for a thorough, systematic
approach in order to show convincingly whether there is a
gap in the evidence base that merits a new trial. For the
other aspects of trial design, there may not be sufficient
available evidence to warrant a systematic review, so that
a less formal description of previous evidence might be
felt to be adequate.
The large proportions of respondents who indicated that
they had either used evidence synthesis to inform trial ana-
lysis or that they believed evidence synthesis should be used
in this way were surprising. Even more surprisingly, a sensi-
tivity analysis including only statisticians provided slightly
lower estimates of these proportions, although the small
sample size precludes strong assertions. We feel that it is
unlikely that these relatively advanced methods are being
used so frequently in practice. As such, we suggest that
many respondents may have interpreted these questions in
ways other than intended. This explanation appears to be
supported by the result that fewer statisticians than nonsta-
tisticians claim to be using external evidence in this way: it
is likely that confusion about these questions was higher
among nonstatisticians although we have no direct evidence
of this. In particular, respondents might have interpreted the
incorporation of ‘external information about the treatment
effect (including a meta-analysis)’ in trial analysis as meaning
including the new trial results in an updated meta-analysis.
Our intention had instead been to elicit views on the use of
informative prior distributions in a Bayesian statistical
framework. In retrospect, we should have clarified these
questions about relatively complex issues using examples,
although we were keen to be as concise as possible. We
propose that future qualitative research should be con-
ducted to explore the use of informative priors with
particular focus on evidence about the treatment effect,
potential biases and other quantities in trial analysis [19].
This work should investigate more thoroughly how trialists
are currently using evidence synthesis to inform analysis,
and the potential barriers to an increased amount of such
use. We would anticipate more objections in principle to
the use of informative prior distributions compared with
less formal uses of evidence synthesis. The qualitative work
should explore which types of external evidence might be
considered most relevant and useful to trial analysis, and
what level of such use might be acceptable in practice.
Funders of clinical trials often highlight the import-
ance of taking into account existing evidence in grant
applications [20]. However, it is still unclear how, and to
what extent, funders or reviewers expect evidence syn-
thesis to be used. We did not explore the views of fun-
ders or reviewers specifically but this could be another
valuable avenue for future research, given the critical
role that they could play in minimising research wastage.
The INVEST survey provides generally higher estimates
of the use of systematic reviews in trial design than the
recent review of Bhurke et al. [7], with the exception of
‘justification of the trial’ (Bhurke et al. 94% versus INVEST
73%). For example, 68% of our respondents indicated that
they had used a systematic review to inform choice of out-
comes and follow-up time, whereas only 16% and 6% of
trials reviewed by Bhurke et al. had used a review to inform
these two aspects, respectively. Similarly, 51% of our
respondents said that they had used a systematic review to
inform sample size calculations, seemingly in contrast to
the finding of Bhurke et al. that only 9% of trials had used a
review to inform the standard deviation and 3% to ‘estimate
the difference to detect or margin of equivalence’. It is pos-
sible that other trials in the Bhurke et al. review relied on
pilot trials to inform these parameters [21, 22], while the
INVEST results seem to suggest that relevant information
will often be available from evidence syntheses. However,
the results are not directly comparable since we asked
respondents to consider all trials that they had been
involved in during the last 10 years, whereas Bhurke et al.
investigated whether evidence synthesis had been used in
specific individual trials. On the other hand, Bhurke et al.
reviewed only publicly funded (NIHR HTA) trials, while
trialists attending ICTMC are likely to also participate in
company-funded trials, for which less justification is re-
quired and there is possibly a stronger expectation for inde-
pendently clear results. In agreement with Bhurke et al. we
found that important barriers to the use of evidence synthe-
sis in practice include a new trial being the first in its area
or being different from trials included in a previous review.
However, by directly asking trialists instead of relying on
documentation, we were able to see that the greatest barrier
is time constraints. In attempt to overcome the issue of
time constraints when synthesising evidence, many methods
for rapid reviews have been proposed over recent years
[23, 24]. Khangura et al. [23] developed their own eight-
step approach of conducting a rapid review having reviewed
the current literature. Implementation of their approach in
HTA trials has been successful and can be applied to other
types of trials [25]. However, more training on approximate
methods and rapid reviews is needed to support their wider
use in practice. Investment in adequate resources and train-
ing at this stage could lead to cost savings in the longer
term, by reducing waste in research.
We found less support for the use of NMAs, decision
models and VoI analyses in trial design which may be
because they are more complex to conduct and require a
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greater investment of time and expertise. These methods
could further help inform decisions but also require add-
itional assumptions and ‘a priori’ parameter estimates,
such as the cost-effectiveness threshold and parameters
related to structural uncertainties in the case of VoI,
which may not be available. A policy framework on when,
and how, to perform such analyses and how they are used
could be a useful next step [26]. We also note that most
individual trials investigate a specific research ques-
tion for one particular treatment: for example, in
2014, 80% of trials were still two-armed trials [27]. In
contrast, NMAs, decision models and VoI analyses are
commonly used to make decisions and inform policy
when there is a choice between a number of concurrent
treatment options. These methods could be considered
less relevant in the design and analysis of an individual
two-armed trial. VoI analyses, in particular, are usually
commissioned in high-value trials, often in situations
with many treatments and uncertainty as to which is
best. However, a NMA could be more relevant to in-
form the interventions of a two-armed trial if used at
the earlier part of the design process [28]. Trial-based eco-
nomic analysis are sometimes secondary to the clinical as-
pect rather than being fully integrated within a trial design
[29] meaning that the use of decision models and VoI ana-
lyses to inform trial design is limited. Only 6% (5/84) of our
respondents had used a VoI analysis to inform whether a
trial is needed, although all of those who had used a VoI
analysis were in favour of its use more generally. Models in
health economic analyses are a strongly simplified rep-
resentation of disease history and treatment effects and
are framed around a particular decision setting (e.g.
UK) using setting-specific values for health care use,
costs and health benefits. These values may change
over time and are likely to be different in other settings.
Streamlining of decision modelling and VoI analyses
would, therefore, be particularly challenging. Despite
the recognition that the VoI method does come with its
assumptions and limitations, its potential to guide the
need for and the design of new studies [30] warrant its
wider consideration and further development.
Conclusions
Trial teams responding to the INVEST survey gener-
ally reported that they are using evidence synthesis in
trial design and analysis more than we might have ex-
pected, but less than they might like to. Time con-
straints was identified as the greatest barrier to more
widespread use. Further research on ways to under-
take evidence synthesis more efficiently, and training
on how to incorporate results from these into existing
procedures will help to ensure the best use of relevant
external evidence in the design, conduct and analysis
of clinical trials.
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